| MTX group (n = 78) | Control group (n = 78) | ||||||
---|---|---|---|---|---|---|---|---|
Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | |
Platelet decreaseda | 11(14%) | 6(8%) | 4(5%) | 0 | 10(13%) | 2(3%) | 4(5%) | 0 |
Neutrophil decreaseda | 18(23%) | 13(16%) | 0 | 0 | 21(27%) | 5(6%) | 0 | 0 |
Cytomegalovirus infection | 50 (64%) | 3 (4%) | 0 | 0 | 48 (62%) | 1(1%) | 0 | 0 |
Cardiac | 5(6%) | 0 | 0 | 0 | 4(5%) | 0 | 0 | 1(1%) |
Gastrointestinalb | 3(4%) | 0 | 0 | 0 | 3(4%) | 2(3%) | 1(1%) | 0 |
Hepatobiliary/pancreatic disorders | 0 | 0 | 0 | 0 | 2(3%) | 1(1%) | 0 | 0 |
Investigationsb | 17(22%) | 3(4%) | 0 | 0 | 18(23%) | 4(5%) | 1(1%) | 1(1%) |
Metabolism and nutrition disorders | 14(18%) | 2(3%) | 0 | 0 | 13(17%) | 4(5%) | 0 | 0 |
Nervous system disorders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1(1%) |
Renal/genitourinary | 10(13%) | 0 | 0 | 0 | 13(17%) | 1(1%) | 0 | 1(1%) |
Vascular | 2(3%) | 5(6%) | 0 | 0 | 2(3%) | 4(5%) | 0 | 0 |
Infectionsc | 8(10%) | 1(1%) | 0 | 2(3%) | 8(10%) | 0 | 0 | 2(3%) |
Secondary malignancyd | - | 1(1%) | 0 | 0 | - | 0 | 0 | 0 |
mucositis | 16(21%) | 2(3%) | 0 | 0 | 22(28%) | 0 | 0 | 0 |